An early report of a p53 and k-ras peptide vaccine trial demonstrated a response rate of ~42% HNSCC patients with an increased frequency of IFN-γ producing CTLs, associated with their prolonged survival (Carbone et al., 2005). This evidence concerns the gene KRAS and head and neck squamous cell carcinoma.